Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Deferred Tax Liability of $7.0 billion for Q1 2026, up 3.24% sequentially from $6.8 billion in Q4 2025, and up 188.76% YoY from $2.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $7.0 billion in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 188.76% year-over-year to $7.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 billion (up 188.76% YoY) and the FY2025 annual result came in at $6.8 billion, up 177.41% from the prior year.
- Non-Current Deferred Tax Liability improved to $7.0 billion in Q1 2026 per JNJ's latest filing, from $6.8 billion in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $7.5 billion in Q1 2022, with the low at $2.4 billion in Q1 2025.
- Average Non-Current Deferred Tax Liability over 5 years is $4.4 billion, with a median of $3.9 billion recorded in 2023.
- Year-over-year, Non-Current Deferred Tax Liability slumped 46.97% in 2023 and jumped 188.76% in 2026.
- Johnson & Johnson's Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then slumped by 35.44% to $3.2 billion in 2023, then dropped by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then climbed by 3.24% to $7.0 billion in 2026.
- Business Quant data shows JNJ's Non-Current Deferred Tax Liability at $7.0 billion in Q1 2026, $6.8 billion in Q4 2025, and $6.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 7.01 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Dec 31, 2023 | 3.19 Bn |